The Anti-VEGF Market is led by established therapies such as Eylea, Lucentis, and Beovu. Market Research Future identifies Eylea as the largest product segment, supported by its established efficacy and broad use in retinal disease treatment.

Eylea is used in the treatment of several retinal conditions, including age-related macular degeneration and diabetic macular edema. Its established clinical profile has contributed to strong adoption among ophthalmologists.

Lucentis remains another significant product in the market, while Beovu represents an important newer option. Competition among these products is encouraging pharmaceutical companies to invest in improved formulations and dosing approaches.

The emergence of biosimilars is also changing the competitive landscape. Biosimilar products may provide additional treatment options and potentially improve affordability and access in selected healthcare systems.

As competition increases, manufacturers are likely to focus on product differentiation, treatment duration, delivery technologies, and clinical evidence.